EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieOpen Access

Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata

Yael Renert-Yuval iD, Ana B Pavel iD, Ester Del Duca, Paola Facheris, Angel D Pagan, Swaroop Bose, Pedro J Gómez-Arias, Michael Angelov, Jennifer Bares, Margo Chima, Yeriel D Estrada, Sandra Garcet und 3 weitere

Allergy · 2023-04 · 78 (4) · 1047-1059

DOI: 10.1111/all.15561 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Allergy, online erschienen am 05.11.2022. Verfasst von Yael Renert-Yuval und 14 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Inflammatory Skin Diseases, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA. Hauptthemen laut MEDLINE: Alopecia Areata. Die Arbeit wurde bisher 59-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCATS NIH HHS, National Center for Advancing Translational Sciences, Regeneron Pharmaceuticals.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The mechanisms driving alopecia areata (AA) are still unclear, hindering development of targeted therapeutics. Specific Th2 targeting with dupilumab in AA provides a unique opportunity to dissect its pathogenesis and explore the role of Th2 pathway.

Methods

We evaluated changes in scalp biomarkers in AA patients (with and without concomitant atopy) randomized to weekly dupilumab or placebo for 24 weeks, followed by open‐label dupilumab for 24 weeks. Changes in biomarker levels were measured at weeks 12, 24, and 48 and were also correlated with clinical hair regrowth.

Results

At week 24, preceding clinical hair regrowth outcomes, only dupilumab‐treated patients presented significant suppression of cellular infiltrates, and multiple Th2‐related, markers (CCL13/MCP‐4, CCL18/PARC, CCL26/eotaxin‐3, CCL24/Eotaxin‐2), coupled with significant upregulation in the hair keratins. Th1‐related suppression was evident later (week 48) when all patients received open‐label dupilumab. Results were more pronounced in atopic AA patients, that showed 48% and 97% improvements in the lesional AA scalp profile at weeks 24 and 48, respectively, while 2% worsening was seen in the placebo arm at week 24. Moreover, placebo‐treated patients presented 54% worsening in hair keratins when compared with baseline at week 24. At week 24, increases in hair keratins showed significant correlations only with decreases in Th2‐related markers.

Conclusions

Scalp biomarkers provide evidence of dupilumab efficacy in AA, detected even prior to clinical response, with exclusive correlations between early suppression of Th2 markers and increased hair keratins. These findings strengthen previous reports suggesting a possible role for Th2 cytokines as AA drivers.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Alopecia AreataHumansScalpKeratins, Hair-SpecificVirulenceBiomarkersAntibodies, Monoclonal, Humanized

Stichwörter der Autor:innen

IgEatopic dermatitisbiologicsclinical immunologydermatology

Substanzen

Keratins, Hair-SpecificBiomarkersdupilumabAntibodies, Monoclonal, Humanized

Autor:innen und Institutionen

  • Laboratory of Inflammatory Skin Diseases, Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, New York, USA.
  • Laboratory for Investigative Dermatology, Rockefeller University, New York, New York, USA.
  • Department of Dermatology, University of Magna Graecia, Catanzaro, Italy.

ORCID-Profile: Yael Renert-Yuval, Ana B Pavel, Mark G Lebwohl, Emma Guttman-Yassky

Förderung

  • NCATS NIH HHS
  • National Center for Advancing Translational Sciences
  • Regeneron Pharmaceuticals

Zitieren

APA

Renert-Yuval, Y., Pavel, A. B., Del Duca, E., Facheris, P., Pagan, A. D., Bose, S., Gómez-Arias, P. J., Angelov, M., Bares, J., Chima, M., Estrada, Y. D., Garcet, S., Lebwohl, M. G., Krueger, J. G., & Guttman-Yassky, E. (2023). Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata. Allergy, 78(4), 1047-1059. https://doi.org/10.1111/all.15561

Vancouver

Renert-Yuval Y, Pavel AB, Del Duca E, Facheris P, Pagan AD, Bose S, et al. Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata. Allergy. 2023;78(4):1047-1059. doi:10.1111/all.15561

BibTeX
@article{RenertYuval2023,
  author = {Renert-Yuval, Yael and Pavel, Ana B and Del Duca, Ester and Facheris, Paola and Pagan, Angel D and Bose, Swaroop and Gómez-Arias, Pedro J and Angelov, Michael and Bares, Jennifer and Chima, Margo and Estrada, Yeriel D and Garcet, Sandra and Lebwohl, Mark G and Krueger, James G and Guttman-Yassky, Emma},
  title = {Scalp biomarkers during dupilumab treatment support Th2 pathway pathogenicity in alopecia areata},
  journal = {Allergy},
  year = {2023},
  volume = {78},
  number = {4},
  pages = {1047--1059},
  doi = {10.1111/all.15561}
}
Kostenlos starten →